Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
2022 · Nature Medicine · 379 citations
https://doi.org/10.1038/s41591-022-01935-8
J
Julia Furtner
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
271
Papers
4.8K
Citations
36
h-index
97
i10-index
Julia Furtner is an academic researcher from Danube Private University. The author has contributed to research in topics: Glioma Diagnosis and Treatment & Brain Metastases and Treatment & Radiomics and Machine Learning in Medical Imaging. The author has an h-index of 36, co-authored 231 publications.
ORCID: 0000-0001-8258-3681Papers by this author
worksThe DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space
2018 · Nature Medicine · 305 citations
https://doi.org/10.1038/s41591-018-0156-x
Invasion patterns in brain metastases of solid cancers
2013 · Neuro-Oncology · 245 citations
https://doi.org/10.1093/neuonc/not112
Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases
2018 · Journal of Neuro-Oncology · 94 citations
https://doi.org/10.1007/s11060-018-2948-8
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
2024 · Neuro-Oncology · 51 citations
https://doi.org/10.1093/neuonc/noae123
Distributed changes of the functional connectome in patients with glioblastoma
2020 · Scientific Reports · 44 citations
https://doi.org/10.1038/s41598-020-74726-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat